After illness, the boundaries of daily life contract almost imperceptibly. A trip that once felt routine — like driving to Tamarack, West Virginia, a place I’ve known for years — suddenly feels ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and ...

OSTEOPATHIC manipulative treatment (OMT) may improve pulmonary function in asthma, though current evidence remains limited and methodologically inconsistent.

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

For children with single-ventricle disease, death or major morbidity occurs in 87%, and shunt type impact varies.

Dhaka, March 20 -- Dhaka, the densely populated capital of Bangladesh, ranked 10th among the world's most polluted cities on Friday morning, recording an Air Quality Index (AQI) of 126 at 11:15 am.

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

The updated 2024-2025 mRNA COVID-19 vaccine was linked to moderate protection against severe COVID-19 outcomes, including hospitalizations.

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD exacerbation with a dry powder inhaler vs. a metered-dose or soft mist ...

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct pulmonary vascular disease caused by chronic obstruction of major pulmonary arteries that is amenable to cure by pulmonary ...